Pacira BioSciences PCRX

Mr. Frank D. Lee. Background and career highlights: Pacira BioSciences (Nasdaq: PCRX), CEO (since 2024). Forma Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, CEO (2019-2022, when acquired by Novo Nordisk A/S). Genentech (a member of the Roche Group), a biotechnology company (2006-2019), SVP, Global Product Strategy, Immunology, Ophthalmology, and Infectious Diseases (2016-2019), and roles of increasing seniority and scope including VP HER2 Franchise and VP Oral Oncolytics Franchise (2006-2016). Novartis AG (NYSE: NVS), a pharmaceutical R\&D and drug development company, Executive Director, Marketing (2003-2006). Johnson & Johnson (NYSE: JNJ), a global pharmaceutical healthcare company (1996-2003), roles of increasing scope and responsibility in sales, marketing, Business Development and Product Strategy. Eli Lilly & Co. (NYSE: LLY), a multi-national pharmaceutical company, Project Management & Process Automation Engineer (1989-1994). Education: B.S., Vanderbilt University; MBA, The Wharton School of Business, University of Pennsylvania. Public company boards: Bausch Health Companies (since 2024), Bolt Biotherapeutics (2021-2024), and Forma Therapeutics (2019-2022). Other directorships: Therini Bio (2023-2024) and Catamaran Bio (2022-2024).

Mr. Brendan P. Teehan. Background and career highlights: Pacira BioSciences (Nasdaq: PCRX), Chief Commercial Officer (since 2025). Acadia Pharmaceuticals (Nasdaq: ACAD), a biopharmaceutical company, EVP, Chief Operating Officer, Head of Commercial (2021-2024), SVP, Chief Analytics & Insights Officer (2021-2022), and VP, Commercial Insights, Analytics & Operations (2018-2021). Held various senior leader and commercial leadership roles at Tesaro, RainTree Oncology, Amgen, and Johnson & Johnson. Education: B.A., University of Notre Dame; MBA, Carnegie Mellon University.

Dr. Jonathan Slonin, M.D. Background and career highlights: Pacira BioSciences (Nasdaq: PCRX), Chief Medical Officer (since 2023), Chief Clinical Officer (2021-2023), and SVP, Strategic Accounts (2020-2021). TeamHealth, a physician-led healthcare organization, Regional Medical Director, Southeast, Anesthesia (2016-2020). Cleveland Clinic Martin Health Center Hospital, Facility Medical Director and Chair, Anesthesiology (2013-2016). Lawnwood Regional Medical Center, Anesthesiologist (2005-2013). Education: B.Sc. and MD, University of Miami; Anesthesiology Residency, University of Miami / Jackson Memorial Hospital; MBA, George Washington University.

Ms. Kristen Marie Williams. Background and career highlights: Pacira BioSciences (Nasdaq: PCRX), Chief Administrative Officer and Secretary (since 2014), VP, General Counsel (2013-2014), Corporate Counsel (2011-2013), and Legal Consultant (2011). Bioenvision, a biopharmaceutical company focused on compounds for cancer treatment, VP, Corporate Compliance and Assistant General Counsel (2004-2007, until merger with Genzyme Corporation). Paul Hastings, a global corporate law firm, Attorney, Corporate Law (1999-2004). Education: B.S., Bucknell University; JD, University of Denver, College of Law.

Mr. Shawn M. Cross. Background and career highlights: Pacira BioSciences (Nasdaq: PCRX), Chief Financial Officer (since 2024). Applied Molecular Transport (Nasdaq: AMTI), a biopharmaceutical company focused on novel, oral biological therapeutics, CEO (2023, through closing of the merger with Cyclo Therapeutics (Nasdaq: CYTH) in December 2023), President, COO (2022-2023), and CFO (2020-2022). JMP Securities, an investment bank, Managing Director, Healthcare Investment Banking (2018-2020). Held various senior roles at Deutsche Bank and Wells Fargo Securities. Education: B.S., University of California, Los Angeles; MBA, Columbia Business School.

Ms. Laura A. Brege. Background and career highlights: BridgeBio Pharma (Nasdaq: BBIO), a clinical-stage biopharmaceutical company, Senior Advisor (since 2018). Cervantes Life Science Partners, a healthcare advisory and consulting company, Managing Director (2015-2018). Nodality, a biotechnology company, President and CEO (2012-2015). Onyx Pharmaceuticals, an oncology focused biopharmaceutical company, Head of Corporate Affairs (2011), COO (2010-2011), and EVP, CBO (2006-2010). Red Rock Capital Management, a venture capital firm, General Partner (1999-2006). COR Therapeutics, a biotechnology company focused on cardiovascular diseases, SVP and CFO (1991-1999). Education: B.A., Ohio University; MBA, University of Chicago. Public company boards: Edgewise Therapeutics (since 2020), Mirum Pharmaceuticals (since 2019), Acadia Pharmaceuticals (since 2008), and HLS Therapeutics (2019-2024).

Ms. Alethia Young. Background and career highlights: Bicycle Therapeutics (Nasdaq: BCYC), a clinical-stage biopharmaceutical company, Advisor (since 2026) and CFO (2023-2026). Graphite Bio, a clinical-stage gene editing company, CFO (2022-2023). Cantor Fitzgerald, a leading global financial services firm, Senior Biotech Analyst and Head of Healthcare Research (2018-2022). Credit Suisse, Deutsche Bank, Marwood Group and J.P. Morgan, leading global financial service firms, various biotech and healthcare-focused advisory and analyst positions (2000-2018). Education: B.A., Duke University. Public company boards: PTC Therapeutics (since 2022).

Mr. Michael J. Yang. Background and career highlights: ViaCyte, a regenerative medicine company developing novel cell replacement, President and CEO (2021-2022). Acadia Pharmaceuticals (Nasdaq: ACAD), a biopharmaceutical company, EVP, Chief Commercial Officer (2017-2021). Janssen Pharmaceuticals (subsidiary of Johnson & Johnson), a biotechnology company, President, Immunology (2013-2017) and President, U.S. Central Nervous Systems (2011-2013). Johnson & Johnson (NYSE: JNJ), a global pharmaceutical healthcare company, various commercial leadership positions (1997-2011). Education: B.S., San Diego State University. Public company boards: Ionis Pharmaceuticals (since 2023). Other directorships: The Scintillon Institute (since 2026) and ViaCyte (2021-2022).

Dr. Mark I. Froimson, M.D. Background and career highlights: Lazurite, a medical device company, CEO (since 2024) and Board Chair (since 2017). Riverside Health Advisors, a healthcare company investment firm, Founder and Principal (since 2017). American Association of Hip and Knee Surgeons, President (2017-2018). Trinity Health, a nationwide, non-profit health care system, EVP and Chief Clinical Officer (2014-2017). Euclid Hospital, a Cleveland Clinic hospital, President and CEO (2012-2014). Cleveland Clinic Department of Orthopedic Surgery, an academic medical center, variety of leadership positions, including staff surgeon (1999-2014). Education: B.S., Princeton University; M.D., Tulane University School of Medicine; MBA, Weatherhead School of Business at Case Western Reserve University. Public company boards: SINTX Technologies (2020-2025). Other directorships: Lazurite (since 2017) and Thrive (since 2018).

Dr. Marcelo Bigal, M.D.,PhD. Background and career highlights: Ventus Therapeutics, a clinical-stage biopharmaceutical company, President and CEO (since 2019). Versant Ventures, a healthcare venture capital firm, Venture Partner (2019-2023). Purdue Pharma, a pharmaceutical company, Chief Medical Officer and SVP (2018-2019). Teva Pharmaceutical Industries (NYSE: TEVA), a global pharmaceutical company, Head of Specialty R\&D and Chief Scientific Officer (2017-2018), Chief Medical Officer and Head of Global Specialty Clinical Development (2017), and numerous management positions of increasing responsibility (2014-2017). Labrys Biologics, a biotechnology company (acquired by Teva Pharmaceuticals), Chief Medical Officer (2013-2014). Merck (NYSE: MRK), a global healthcare company, Head of Investigator Study Program, Scientific Engagement and Education (2010-2013) and Global Director of Scientific Affairs, Neurology and Psychiatry (2007-2010). Education: M.D., University of Sao Paulo; Ph.D., University of Sao Paulo. Other directorships: Eurofarma Laboratorios (since 2026), Santa Ana Bio (since 2023), Ventus Therapeutics (since 2019), and Coda Biotherapeutics (2019-2022).

Governor Christopher J. Christie. Background and career highlights: Christie 55 Solutions, a government and public policy consulting firm, Managing Member (since 2018). Yale University, Senior Fellow, Jackson School of Global Affairs (since 2024). 55th Governor of the State of New Jersey (2010-2018), U.S. Opioid and Drug Abuse Commission, Chair (2017), and United States Attorney of the State of New Jersey (2002-2008). Education: B.A., University of Delaware; JD, Seton Hall University School of Law. Other directorships: Saker Holdings (since 2019), New York Mets (since 2021), and Tenneco (since 2024).

Mr. Thomas G. Wiggans is appointed as Director at AGM on June 9, 2026. Background and career highlights: Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company, Chairman and CEO (2022-2023). Dermira, Inc. (Nasdaq: DERM), a biopharmaceutical company, Co-Founder, CEO, and Director (2010-2020). Peplin, Inc., a specialty pharmaceutical company, CEO and Chairman of the Board (2007-2009). Connetics Corporation (Nasdaq: CNCT), a dermatology pharmaceutical company, CEO and Director (1994-2005), and CEO and Chairman (2005-2006). Cytotherapeutics, Inc. (Nasdaq: CYTO), a biotechnology company, COO and Director (1992-1994). Education: B.S., Pharmacy, University of Kansas; MBA, Southern Methodist University. Public company boards: Jasper Therapeutics (since 2023), Annexon (2017-2026), Pardes Biosciences (2022-2023), CymaBay Therapeutics (2021-2024), and Forma Therapeutics (2020-2022). Other directorships: Biotechnology Innovation Organization-Founding Member (since 1993).

Ms. Riker will continue to serve as the Company's Senior Vice President of Finance and as Principal Accounting Officer. Lauren Riker has served as our principal accounting officer since March 2012 and our Executive Director, Accounting and Financial Reporting since March 2011. Prior to joining us, Ms. Riker served as Senior Director of Financial Reporting at Ikaria, Inc. (Ikaria), a private critical care biopharmaceutical company, from April 2008 to April 2011, where she was responsible for the oversight, monitoring and review of Ikaria's financial reporting, technical accounting and stock-based compensation program. From December 2004 to February 2008, Ms. Riker served as the Controller and later the Chief Accounting Officer of Bioenvision, Inc., (Bioenvision) a publicly traded biotechnology company. Her responsibilities at Bioenvision included preparation of the financial statements and disclosures in accordance with United States generally accepted accounting principles and the reporting requirements of the SEC and implementation of internal controls and procedures in compliance with Sarbanes-Oxley. From 2000 to 2004, Ms. Riker worked at KPMG in the Information, Communication and Entertainment sector where she held positions of increasing responsibility, including Audit Manager. Ms. Riker holds a B.S. in accounting from Boston College and an M.B.A. from Columbia Business School. On September 26, 2024, the Board of Directors of the Company (the Board) appointed Lauren Riker, the Company's current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company effective October 1, 2024. Ms. Riker served as interim Chief Financial Officer from October 1, 2024 to October 20, 2024.

On January 27, 2026, the Board of Directors of Pacira BioSciences, Inc. and appointed Dr. Samit Hirawat to the Board, to serve as a Class III director, effective immediately. Most recently, Dr. Hirawat served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic and operational responsibility, culminating in his position as Executive Vice President and Head of Oncology Development. Dr. Hirawat earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College, where he also trained as a Resident in General Surgery. He conducted his Internal Medicine residency and Medical Oncology fellowship at North Shore University Hospital. Dr. Hirawat has published more than 150 peer-reviewed manuscripts and abstracts across therapeutic areas.